JeromeLewisAvornMD

PubMed

• 4 citations
  Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.
  Alexis A. Krumme, Ajinkya Pawar, Sebastian Schneeweiss, Robert J. Glynn, Niteesh K. Choudhry, Martin Kulldorff, Adrian J. Santiago Ortiz, Jerome Avorn, Joshua J. Gagne> ;Journal of Comparative Effectiveness Research. 2018 Jan 1
• Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
  Sarpatwari, A.,Franklin, J. M.,Avorn, J.,Seeger, J. D.,Landon, J. E.,Kesselheim, A. S.> ;Clin. Pharmacol. Ther.. 2015 Feb 12
• Clinical and regulatory features of drugs not initially approved by the FDA.
  Wang, B.,Avorn, J.,Kesselheim, A. S.> ;Clin. Pharmacol. Ther.. 2013 Aug 22
• Defining 'Innovativeness' in Drug Development:A Systematic Review
  Jerry Avorn, Bo Wang> ;Wiley. 2013 Sep
• Changing Interactions Between Physician Trainees and the Pharmaceutical Industry: A National Survey
  Kirsten E Austad, Jerry Avorn, Aaron S Kesselheim> ;Springer.
• Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.
  Solomon, D. H.,Mercer, E.,Woo, S. B.,Avorn, J.,Schneeweiss, S.,Treister, N.> ;Osteoporos Int. 2013 Jan
• Drug labels: a flawed source of data for studying orphan drug approvals.
  Kesselheim, A. S., Avorn, J.> ;Clin Pharmacol Ther. 2012 Dec
• Adverse pulmonary effects of topical Beta blockers used in the treatment of glaucoma.
  Avorn, J.,Glynn, R. J.,Gurwitz, J. H.,Bohn, R. L.,Monane, M.,Everitt, D. E.,Gilden, D.,Choodnovskiy, I.> ;J. Glaucoma. 1993 Oct 01
• Join now to see all